Posted by admin on May 13th, 2022
Fanuc Co. (OTCMKTS:FANUY – Get Rating) saw a large growth in short interest in April. As of April 30th, there was short interest totalling 271,800 shares, a growth of 139.1% from the April 15th total of 113,700 shares. Based on an average trading volume of 948,200 shares, the days-to-cover ratio is presently 0.3 days.
OTCMKTS:FANUY opened at $14.92 on Friday. Fanuc has a 52-week low of $14.25 and a 52-week high of $25.51. The firm has a market cap of $30.13 billion, a price-to-earnings ratio of 21.01 and a beta of 1.04. The business’s fifty day moving average is $16.54 and its 200 day moving average is $18.91.
A number of brokerages recently issued reports on FANUY. Bank of America cut Fanuc from a “buy” rating to a “neutral” rating in a report on Thursday, February 17th. JPMorgan Chase & Co. cut Fanuc from a “neutral” rating to an “underweight” rating in a research report on Monday, March 7th. Finally, Zacks Investment Research raised Fanuc from a “sell” rating to a “hold” rating in a research report on Wednesday, April 20th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and one has issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $26.00.
Fanuc Company Profile (Get Rating)
Fanuc Corporation provides factory automation products in Japan, the Americas, Europe, China, the rest of Asia, and internationally. The company offers CNC series products, servo motors, lasers, robots, compact machining centers, electric injection molding machines, wire electrical discharge machines, and ultra-precision machines.
Receive News & Ratings for Fanuc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fanuc and related companies with MarketBeat.com's FREE daily email newsletter.
Tennessee Valley Authority PARRS A 2029 (NYSE:TVE) Sees Significant Growth in Short Interest
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives Consensus Rating of “Buy” from Analysts